All In Biotech

Drug Trial Radar · NCT05336071

The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects

Study on Bioavailability Study of INS068 Injection by Subcutaneous Injection of New and Old Formulations in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 12, 2022

Primary completion

May 26, 2022

Study completion Jun 2, 2022

Sponsor

Sponsor type
Industry
First posted
Apr 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 24 healthy male subjects. Subjects will receive INS068 injection on Day1 and Day8.

Conditions

  • Diabetes Mellitus

Interventions

  • INS068 injectionDrug

    Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.

  • INS068 injectionDrug

    Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed serum concentration (Cmax) of INS068 injectionTime frame: from Day1 to Day5 after the first cycle(each cycle is 5 days) and from Day8 to Day12 after the second cycle(each cycle is 5 days)
  2. Area under the plasma concentration versus time curve (AUC0-t) of INS068 injectionTime frame: from Day1 to Day5 after the first cycle(each cycle is 5 days) and from Day8 to Day12 after the second cycle(each cycle is 5 days)
  3. Area under the plasma concentration versus time curve (AUC0-inf ) of INS068 injectionTime frame: from Day1 to Day5 after the first cycle(each cycle is 5 days) and from Day8 to Day12 after the second cycle(each cycle is 5 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Qian Foshan Hospital of Shandong Province

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.